Hereditary prostate cancer - Primetime for genetic testing?
Standard
Hereditary prostate cancer - Primetime for genetic testing? / EAU-YAU Prostate Cancer Working Group.
in: CANCER TREAT REV, Jahrgang 81, 12.2019, S. 101927.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Hereditary prostate cancer - Primetime for genetic testing?
AU - Heidegger, Isabel
AU - Tsaur, Igor
AU - Borgmann, Hendrik
AU - Surcel, Christian
AU - Kretschmer, Alexander
AU - Mathieu, Romain
AU - Visschere, Pieter De
AU - Valerio, Massimo
AU - van den Bergh, Roderick C N
AU - Ost, Piet
AU - Tilki, Derya
AU - Gandaglia, Giorgio
AU - Ploussard, Guillaume
AU - EAU-YAU Prostate Cancer Working Group
N1 - Copyright © 2019 Elsevier Ltd. All rights reserved.
PY - 2019/12
Y1 - 2019/12
N2 - Prostate cancer (PCa) remains the most common cancer in men. The proportion of all PCa attributable to high-risk hereditary factors has been estimated to 5-15%. Recent landmark discoveries in PCa genetics led to the identification of germline mutations/alterations (eg. BRCA1, BRCA2, ATM or HOXB13), single nucleotide polymorphisms or copy number variations associated with PCa incidence and progression. However, offering germline testing to men with an assumed hereditary component is currently controversial. In the present review article, we provide an overview about the epidemiology and the genetic basis of PCa predisposition and critically discuss the significance and consequence in the clinical routine. In addition, we give an overview about genetic tests and report latest findings from ongoing clinical studies. Lastly, we discuss the impact of genetic testing in personalized therapy in advanced stages of the disease.
AB - Prostate cancer (PCa) remains the most common cancer in men. The proportion of all PCa attributable to high-risk hereditary factors has been estimated to 5-15%. Recent landmark discoveries in PCa genetics led to the identification of germline mutations/alterations (eg. BRCA1, BRCA2, ATM or HOXB13), single nucleotide polymorphisms or copy number variations associated with PCa incidence and progression. However, offering germline testing to men with an assumed hereditary component is currently controversial. In the present review article, we provide an overview about the epidemiology and the genetic basis of PCa predisposition and critically discuss the significance and consequence in the clinical routine. In addition, we give an overview about genetic tests and report latest findings from ongoing clinical studies. Lastly, we discuss the impact of genetic testing in personalized therapy in advanced stages of the disease.
KW - BRCA1 Protein/genetics
KW - BRCA2 Protein/genetics
KW - Checkpoint Kinase 2/genetics
KW - Clinical Trials as Topic
KW - DNA Copy Number Variations
KW - Genetic Predisposition to Disease
KW - Genetic Testing
KW - Homeodomain Proteins/genetics
KW - Humans
KW - Male
KW - Mutation
KW - Polymorphism, Single Nucleotide
KW - Precision Medicine/methods
KW - Prostatic Neoplasms/epidemiology
U2 - 10.1016/j.ctrv.2019.101927
DO - 10.1016/j.ctrv.2019.101927
M3 - SCORING: Review article
C2 - 31783313
VL - 81
SP - 101927
JO - CANCER TREAT REV
JF - CANCER TREAT REV
SN - 0305-7372
ER -